Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Clin Exp Immunol ; 189(3): 310-317, 2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28500641

RESUMEN

Ras-associated lymphoproliferative disease (RALD) is an autoimmune lymphoproliferative syndrome (ALPS)-like disease caused by mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) or neuroblastoma RAS viral (V-Ras) oncogene homologue (NRAS). The immunological phenotype and pathogenesis of RALD have yet to be studied extensively. Here we report a thorough immunological investigation of a RALD patient with a somatic KRAS mutation. Patient lymphocytes were analysed for phenotype, immunoglobulin levels and T cell proliferation capacity. T and B cell receptor excision circles (TREC and KREC, respectively), markers of naive T and B cell production, were measured serially for 3 years. T and B cell receptor repertoires were studied using both traditional assays as well as next-generation sequencing (NGS). TREC and KREC declined dramatically with time, as did T cell receptor diversity. NGS analysis demonstrated T and B clonal expansions and marked restriction of T and B cell receptor repertoires compared to healthy controls. Our results demonstrate, at least for our reported RALD patient, how peripheral T and B clonal expansions reciprocally limit lymphocyte production and restrict the lymphocyte receptor repertoire in this disease. Decreased naive lymphocyte production correlated with a clinical deterioration in our patient's immune status, suggesting that TREC and KREC may be used as an aid in monitoring disease progression. Both the methodologies used here and the conclusions regarding immune homeostasis may be applicable to the research of ALPS and other immune dysregulation syndromes.


Asunto(s)
Síndrome Linfoproliferativo Autoinmune/genética , Síndrome Linfoproliferativo Autoinmune/inmunología , Linfocitos B/fisiología , Genes ras , Mutación , Linfocitos T/fisiología , Linfocitos B/inmunología , Niño , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Fenotipo , Receptores de Antígenos de Linfocitos B/genética , Receptores de Antígenos de Linfocitos B/inmunología , Receptores de Antígenos de Linfocitos T/genética , Receptores de Antígenos de Linfocitos T/inmunología , Linfocitos T/inmunología
2.
Ann Oncol ; 22(7): 1614-1621, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21245159

RESUMEN

BACKGROUND: Outcomes of Ewing tumor (ET) patients treated with allogeneic stem cell transplantation (allo-SCT) were compared regarding the use of reduced-intensity conditioning (RIC) and high-intensity conditioning (HIC) regimens as well as human leukocyte antigen (HLA)-matched and HLA-mismatched grafts. PATIENTS AND METHODS: We retrospectively analyzed data of 87 ET patients from the European Group for Blood and Marrow Transplantation, Pediatric Registry for Stem Cell Transplantations, Asia Pacific Blood and Marrow Transplantation and MetaEICESS registries treated with allo-SCT. Fifty patients received RIC (group A) and 37 patients received HIC (group B). Twenty-four patients received HLA-mismatched grafts and 63 received HLA-matched grafts. RESULTS: Median overall survival was 7.9 months [±1.24, 95% confidence interval (CI) 5.44-10.31] for group A and 4.4 months (±1.06, 95% CI 2.29-6.43) for group B patients (P = 1.3). Death of complications (DOC) occurred in 4 of 50 (0.08) and death of disease (DOD) in 33 of 50 (0.66) group A and in 16 of 37 (0.43) and 17 of 37 (0.46) group B patients, respectively. DOC incidence was decreased (P < 0.01) and DOD/relapse increased (P < 0.01) in group A compared with group B. HLA mismatch was not generally associated with graft-versus-Ewing tumor effect (GvETE). CONCLUSIONS: There was no improvement of survival with RIC compared with HIC due to increased DOD/relapse incidence after RIC despite less DOC incidence. This implicates general absence of a clinically relevant GvETE with current protocols.


Asunto(s)
Neoplasias Óseas/mortalidad , Neoplasias Óseas/terapia , Enfermedad Injerto contra Huésped/terapia , Sarcoma de Ewing/mortalidad , Sarcoma de Ewing/terapia , Trasplante de Células Madre , Adolescente , Adulto , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Tasa de Supervivencia , Acondicionamiento Pretrasplante , Trasplante Homólogo , Resultado del Tratamiento , Adulto Joven
3.
Bone Marrow Transplant ; 50(10): 1337-42, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26146807

RESUMEN

Allogeneic stem cell transplantation (SCT) is widely used for treatment of various life-threatening pediatric diseases. It is an intensive process that psychologically affects the whole family. Pediatric donors represent a very unique, underreported, group. The aim of this study is to investigate the sibling donors' and their parents' perspective on the donation process. The cohort included 36 sibling donors and 50 parents of pediatric patients who underwent allogeneic SCT between 1995 and 2010 and were alive at the time of the study. Mean age at donation was 14.78±8.350 years in donors' group and 8.22±4.639 years in parents' group. Data were collected by anonymous questionnaires. Three psychological dimensions were analyzed: donors' personal perspective; donor-recipient interpersonal relationship and the influence of the donation on the family unit. Results showed that the donors experienced a wide range of complex emotional responses, positive and negative, whereas the parents' responses were mainly positive and less complex. This study presents both the sibling donor's and parents' perspective, giving a more complete picture of the donation process within the family. The effects of this intense experience of SCT has a long-term impact on the whole family, indicating the need for follow-up and psychosocial support.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas/psicología , Donadores Vivos/psicología , Hermanos/psicología , Acondicionamiento Pretrasplante/psicología , Trasplante Homólogo/psicología , Adolescente , Estudios de Cohortes , Femenino , Humanos , Masculino , Padres , Encuestas y Cuestionarios
4.
Transplantation ; 70(7): 1100-4, 2000 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-11045650

RESUMEN

BACKGROUND: Immunotherapy given post-autologous stem cell transplantation may eliminate residual tumor cells escaping the conditioning protocol. METHODS: Five children suffering from stage IV neuroblastoma were treated by recombinant interleukin-2 (IL-2) post-autologous peripheral blood stem cell transplantation. The patients' peripheral mononuclear cells were monitored for CD3+ and CD56+ levels, their proliferative response and killing of various cell lines targets. RESULTS: An increase in the level of total lymphocytes, mainly due to expansion of T cells, and enhanced proliferative response to phytohemaglutinin were observed. Elevated cytotoxicity against K562 and neuroblastoma target cells was detected in four patients and against K562 targets in one patient. Toxicity included mild thrombocytopenia, and fever in four patients and mild to moderate encephalopathy which necessitated withdrawing one patient from the protocol. Three of five patients studied are alive today, one of them whose IL-2 was stopped, is in relapse. Two patients have died. CONCLUSIONS: Immunotherapy with s.c. intermediate-high dose IL-2 is feasible and results in expansion of T cells and in stimulation of killing activity against several targets including in some cases, neuroblastoma tumor cells.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Interleucina-2/inmunología , Neuroblastoma/patología , Neuroblastoma/cirugía , Preescolar , Relación Dosis-Respuesta Inmunológica , Femenino , Trasplante de Células Madre Hematopoyéticas/mortalidad , Humanos , Inmunoterapia , Lactante , Interleucina-2/uso terapéutico , Activación de Linfocitos/efectos de los fármacos , Masculino , Estadificación de Neoplasias , Tasa de Supervivencia , Linfocitos T/inmunología , Factores de Tiempo , Trasplante Autólogo
5.
Bone Marrow Transplant ; 28(6): 613-4, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11607776

RESUMEN

Hemorrhagic cystitis (HC) is a known complication of stem cell transplantation. In contrast to early-onset HC that is usually attributed to cyclophosphamide and occurs within a few days of infusion, late onset HC is associated with viral infection. In recent years BK virus has emerged as an important causative agent. We describe two patients who developed late onset HC (38 and 92 days post transplant) associated with BK viruria concomitant with CMV reactivation and suggest a possible role of CMV in the process of BK virus DNA replication.


Asunto(s)
Virus BK , Cistitis/etiología , Citomegalovirus/crecimiento & desarrollo , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Infecciones por Polyomavirus , Infecciones Tumorales por Virus , Niño , Preescolar , Cistitis/virología , Ganciclovir/administración & dosificación , Hemorragia/etiología , Hemorragia/virología , Humanos , Masculino , Activación Viral
6.
Bone Marrow Transplant ; 31(10): 931-4, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12748672

RESUMEN

Donor-cell leukemia post bone marrow transplantation is a rare event. Most of the cases reported to date have developed in cells from an HLA-matched sibling, who had no evidence of malignant disease before or following the occurrence of donor-origin leukemia. We describe a 17-year-old female who developed B-cell lymphoma 9 years following the occurrence of donor-origin acute myeloid leukemia in her brother for whom she had donated marrow. Cytogenetic analysis of the tumor revealed multiple chromosomal aberrations. The donor was heterozygous for the Ashkenazi mutation of Bloom's syndrome, suggesting that donor-type leukemia could have resulted from genomic instability in the donor cells.


Asunto(s)
Trasplante de Médula Ósea , Leucemia Mieloide Aguda/terapia , Linfoma de Células B/diagnóstico , Donantes de Tejidos , Quimera por Trasplante/genética , Adolescente , Mapeo Cromosómico , Femenino , Prueba de Histocompatibilidad , Humanos , Linfoma de Células B/genética , Masculino , Hermanos , Factores de Tiempo
7.
Bone Marrow Transplant ; 34(4): 317-20, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15220954

RESUMEN

Successful stem cell transplantation for patients with severe combined immunodeficiency (SCID) from matched family donors without conditioning results in engraftment of T lymphocytes. B lymphocytes engraft in only 50% of the cases, while myelopoiesis and erythropoiesis remain of host origin. Full hematopoietic engraftment was reported in one case after bone marrow transplantation without conditioning for a SCID patient. We studied three SCID patients who were transplanted with unmodified mobilized peripheral blood from HLA-identical family sex-mismatched members. They received megadoses of stem cells (18-23 x 10(6)CD34/kg). In contrast to the expected mixed chimerism that usually occurs in the absence of conditioning, we found in our patients 100% donor cell engraftment based on fluorescence in situ hybridization (FISH) and microsatellite techniques. Subset analysis of the engrafted cells using a multiparametric system enabling a combined analysis of morphology, immunophenotyping and FISH showed that both T and B lymphocytes and myeloid cells were of donor origin in two patients, while T lymphocytes and myeloid cells were of donor origin in the third. In the two cases with ABO incompatibility, erythroid engraftment was evidenced by blood group conversion from recipient to donor type. Multilineage donor engraftment is possible in SCID patients even without conditioning.


Asunto(s)
Transfusión de Linfocitos , Inmunodeficiencia Combinada Grave/terapia , Trasplante de Células Madre/métodos , Linfocitos B/trasplante , Trasplante de Médula Ósea/inmunología , Niño , Preescolar , Familia , Femenino , Antígenos HLA/inmunología , Prueba de Histocompatibilidad , Humanos , Lactante , Masculino , Inmunodeficiencia Combinada Grave/inmunología , Linfocitos T/trasplante , Acondicionamiento Pretrasplante , Trasplante Homólogo , Resultado del Tratamiento
8.
Bone Marrow Transplant ; 26(9): 1025-8, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11100285

RESUMEN

Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder characterized by impaired microbial killing and susceptibility to bacterial and fungal infections. Cure of the disease can be achieved by stem cell transplantation when performed early in its course, and before severe infections have developed. Invasive aspergillosis constitutes a very high risk for transplantation. We report a 4-year-old boy with X-linked CGD who underwent successful HLA-identical peripheral blood stem cell (PBSC) transplantation during invasive pulmonary aspergillosis and osteomyelitis of the left fourth rib, which was unresponsive to antifungal treatment. During the 2 months prior to the transplant he received G-CSF-mobilized granulocyte transfusions (GTX) from unrelated donors three times a week in addition to the antifungal treatment. This resulted in clinical improvement in his respiratory status. He also received GTX during the aplastic period after the conditioning regimen, until he had engrafted. Post-transplant superoxide generation test revealed that neutrophil function was within normal range. One year post transplant the CT scan showed almost complete clearance of the pulmonary infiltrates and a marked improvement in the osteomyelitic process. Based on other reports and our own experience, GTX can serve as important treatment in patients with CGD who have failed conventional anti-fungal treatment and for whom stem cell transplantation is the only chance for cure.


Asunto(s)
Aspergilosis/terapia , Granulocitos/trasplante , Enfermedad Granulomatosa Crónica/complicaciones , Trasplante de Células Madre Hematopoyéticas , Transfusión de Leucocitos , Enfermedades Pulmonares Fúngicas/terapia , Osteomielitis/terapia , Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Aspergilosis/etiología , Preescolar , Terapia Combinada , Farmacorresistencia Microbiana , Flucitosina/uso terapéutico , Factor Estimulante de Colonias de Granulocitos/farmacología , Enfermedad Granulomatosa Crónica/terapia , Humanos , Huésped Inmunocomprometido , Itraconazol/uso terapéutico , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Enfermedades Pulmonares Fúngicas/etiología , Enfermedades Pulmonares Fúngicas/microbiología , Masculino , Neutrófilos/fisiología , Osteomielitis/tratamiento farmacológico , Osteomielitis/etiología , Osteomielitis/microbiología , Pirimidinas/uso terapéutico , Estallido Respiratorio , Costillas/microbiología , Triazoles/uso terapéutico , Voriconazol
9.
Bone Marrow Transplant ; 45(6): 1084-7, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19915629

RESUMEN

Pericardial effusion and cardiac tamponade have been described as GVHD manifestations in the post transplant period. Direct evidence of GVHD-related TCR or B-cell receptor clones in patients with pericardial effusion has never been described. Using several methods, including FACS and spectratyping analysis to assess T- and B-cell clonality and to quantify TCR excision circles to assess newly thymus-derived T cells, we were able to show expansion of oligoclonal T-cell populations and the possible presence of early/premature B cells in the pericardial effusion but not in peripheral mononuclear cells. This may explain the presentation of an isolated GVHD manifestation.


Asunto(s)
Autoantígenos/inmunología , Enfermedad Injerto contra Huésped/inmunología , Derrame Pericárdico/inmunología , Adulto , Linfocitos B/patología , Proliferación Celular , Células Clonales/inmunología , Células Clonales/patología , Femenino , Citometría de Flujo , Enfermedad Injerto contra Huésped/patología , Enfermedades Hematológicas/complicaciones , Enfermedades Hematológicas/terapia , Trasplante de Células Madre Hematopoyéticas , Humanos , Inmunidad , Masculino , Persona de Mediana Edad , Derrame Pericárdico/patología , Linfocitos T/patología , Adulto Joven
10.
Pediatr Blood Cancer ; 48(3): 324-9, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16568442

RESUMEN

BACKGROUND: Patients with childhood cancer or primary immunodeficiencies (PID) are at high risk for developing pulmonary infections and non-infectious complications. The broad differential diagnoses and the critical condition of these patients often drive physicians to start broad-spectrum antibiotic therapy before a definite diagnostic procedure is performed. A definite diagnosis may be achieved in these situations by fiberoptic bronchoscopy (FOB) and bronchoalveolar lavage (BAL). PATIENTS AND METHODS: The records of 58 PIDs and cancer (immunocompromised group) pediatric patients who underwent 62 fiberoptic bronchoscopies between 2000 and 2004 were retrospectively reviewed and compared to 158 non-cancer patients who underwent 182 fiberoptic bronchoscopies during the same period. RESULTS: The overall diagnostic rate achieved by macroscopic inspection of purulent secretions or hemorrhage, abnormal cell count, and infectious agent isolation in the immunocompromised patients was 84%. A definite organism was recovered in 53.2% of the patients. Probable infection defined as purulent secretions or abnormal cell count without infectious agent isolation was diagnosed in another 21% of the patients. The rate of complications was 30.6%. In the control group, the overall diagnostic rate was 76.9% (n.s) and an infectious agent was demonstrated in 12.1% (P < 0.001). Probable infection was diagnosed in 24.2% (n.s) while the rate of complications was lower (15%) (P < 0.01). CONCLUSIONS: Rapid and accurate diagnoses were achieved in most procedures performed on immunocompromised patients. Although the rate of complications was higher in the immunocompromised group, they were usually very mild with no mortality. Based on these results, broncoalveolar lavage should be considered as an initial diagnostic tool in pediatric immunocompromised patients with pulmonary complications.


Asunto(s)
Líquido del Lavado Bronquioalveolar , Broncoscopía/estadística & datos numéricos , Síndromes de Inmunodeficiencia/complicaciones , Enfermedades Pulmonares/diagnóstico , Neoplasias/complicaciones , Adolescente , Adulto , Aspergilosis/diagnóstico , Aspergilosis/microbiología , Aspergilosis/patología , Biopsia , Líquido del Lavado Bronquioalveolar/citología , Líquido del Lavado Bronquioalveolar/microbiología , Líquido del Lavado Bronquioalveolar/virología , Broncoscopios , Broncoscopía/efectos adversos , Broncoscopía/métodos , Niño , Preescolar , Comorbilidad , Femenino , Tecnología de Fibra Óptica , Humanos , Huésped Inmunocomprometido , Lactante , Enfermedades Pulmonares/complicaciones , Enfermedades Pulmonares/microbiología , Enfermedades Pulmonares/patología , Enfermedades Pulmonares Fúngicas/diagnóstico , Enfermedades Pulmonares Fúngicas/microbiología , Enfermedades Pulmonares Fúngicas/patología , Masculino , Neutropenia/complicaciones , Neumonía Bacteriana/diagnóstico , Neumonía Bacteriana/microbiología , Neumonía Bacteriana/patología , Neumonía por Pneumocystis/diagnóstico , Neumonía por Pneumocystis/patología , Neumonía Viral/diagnóstico , Neumonía Viral/patología , Neumonía Viral/virología , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA